Reuters logo
BRIEF-Boehringer Ingelheim announces final results from RE-VERSE AD
July 11, 2017 / 8:48 AM / 4 months ago

BRIEF-Boehringer Ingelheim announces final results from RE-VERSE AD

July 11 (Reuters) - Boehringer Ingelheim:

* Final phase III study results confirm benefit of Praxbind as reversal agent for pradaxa patients in emergency situations

* Announced final results from RE-VERSE AD

* Study shows that praxbind was able to immediately & completely reverse anticoagulant effect of Pradaxa in patients in emergency situations

* Expected completion of RE-VECTO(™) programme is end of 2018

* There were no serious adverse safety signals related to Praxbind(®) observed in study Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below